H.C. Wainwright reaffirmed a Buy rating on Cartesian Therapeutics shares, maintaining the $45.00 price target, representing a ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 28.87% ...
H.C. Wainwright reiterated its Buy rating and $27.00 price target for CleanSpark Inc. (NASDAQ:CLSK) shares, representing ...
H.C. Wainwright has recently reiterated Microbot Medical Inc (MBOT) stock to Buy rating, as announced on January 13, 2020, according to Finviz. Earlier, on December 24, 2019, H.C. Wainwright had ...
Stock analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a research note issued on Thursday, January 23rd. HC Wainwright analyst P.
Research analysts at HC Wainwright decreased their FY2024 earnings per share estimates for Hoth Therapeutics in a note issued to investors on Thursday, January 23rd. HC Wainwright analyst R. Selvaraju ...
H.C. Wainwright raised the firm’s price target on Akero Therapeutics (AKRO) to $72 from $50 and keeps a Buy rating on the shares after the ...
H.C. Wainwright lowered the firm’s price target on Jasper Therapeutics (JSPR) to $40 from $60 and keeps a Buy rating on the shares after the company announced initial data from the BEACON study ...
H.C. Wainwright raised the firm’s price target on ArriVent Biopharma (AVBP) to $39 from $36 and keeps a Buy rating on the ...
H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation and an $11 per share target on Thursday, despite an over 38% drop ...
H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...